Targeting VEGF-A to treat cancer and age-related macular degeneration
N Ferrara, RD Mass, C Campa, R Kim - Annu. Rev. Med., 2007 - annualreviews.org
Inhibiting angiogenesis is a promising strategy to treat cancer and several other disorders,
including intraocular neovascular syndromes. The identification of vascular endothelial
growth factor (VEGF)-A as a major regulator of normal and pathological angiogenesis has
enabled significant progress toward effective treatments for such disorders. Several VEGF
inhibitors have been recently approved by the US Food and Drug Administration for the
treatment of cancer and the neovascular form of age-related macular degeneration. This …
including intraocular neovascular syndromes. The identification of vascular endothelial
growth factor (VEGF)-A as a major regulator of normal and pathological angiogenesis has
enabled significant progress toward effective treatments for such disorders. Several VEGF
inhibitors have been recently approved by the US Food and Drug Administration for the
treatment of cancer and the neovascular form of age-related macular degeneration. This …
